Search Results - sunil+sundalam

2 Results

Sort By:

Covalent inhibitors of PARP-16 for cancer treatment

Summary The current technology is a selective, covalent inhibitor of PARP16 with potential therapeutic applications for the treatment of cancer. Technology Overview The poly-ADP-ribose-polymerase (PARP) family is made up of 17 enzymes in humans that are increasingly recognized as major downstream regulators of NAD+-mediated signaling in cells. PARP1...

Published: 10/15/2024 | Inventor(s): Michael (Mike) Cohen, Daniel Bejan, Sunil Sundalam

Keywords(s): Therapeutics, Therapeutics - Cancer

Category(s): Therapeutics

Clickable, photoactivatable NAD+ analogues as probes for PARP and other NAD+-binding targets

Summary Researchers at OHSU have developed a screening platform for identification of proteins regulated by PARPs, which relies on a novel bi-functional NAD analog containing a photo-reactive group for crosslinking to binding targets and a click tag for their identification. This tool can be used to efficiently screen cell lysates to uncover novel...

Published: 9/21/2023 | Inventor(s): Sunil Sundalam, Michael Cohen

Keywords(s): Research Tools, Therapeutics, Therapeutics - Cancer, Therapeutics - Immunology, Therapeutics - Infectious Diseases

Category(s): Chemical, Research Tools, Therapeutics